The Alternative Approach: Addressing Root Causes What if we could address the underlying drivers of eczemamicrobial dysbiosis, barrier dysfunction, and immune dysregulationrather than simply suppressing inflammation
How Does BPC-157 Compare to TB-500? BPC-157 is frequently stacked with or compared to TB-500 (thymosin beta-4 fragment)
Here are some of the most common inquiries we address to help researchers refine their protocols
In SURMOUNT-1 , a 72-week Phase 3 double-blind trial in 2,539 adults with obesity (or overweight with a complication) but without diabetes, once-weekly tirzepatide produced mean weight changes of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% with placebo, with 5057% of participants on the higher doses losing at least 20% of body weight
I am usually back to my usual sleeping patterns the following day
Karla has worked with patients exploring wellness-focused peptide programs, including BPC-157, TB-500, GLOW Mix, KLOW Peptide Therapy, Ipamorelin, Sermorelin, Tesamorelin, NAD+ therapy, and physician-guided medical weight loss programs
